Abstract
The leukocyte immunoglobulin–like receptor (LILR)B3 and LILRA6 genes encode homologous myeloid inhibitory and activating orphan receptors, respectively. Both genes exhibit a strikingly high level of polymorphism at the amino acid level and LILRA6 (but not LILRB3) displays copy number variation (CNV). Although multiple alleles have been reported for both genes, limited data is available on frequencies of these alleles among humans. We have sequenced LILRB3/A6 exons encoding signal peptides and ectodomains in 91 healthy blood donors of European descent who carry one or two copies of LILRA6 per diploid genome. Analysis of haplotypes among individuals with two LILRA6 copies, representing the majority in this cohort (N = 86), shows that common LILRB3 and LILRA6 alleles encode some distinct amino acid sequences in homologous regions of the receptors, which could potentially impact their respective functions differentially. Comparison of sequences in individuals with one vs. two copies of LILRA6 supports non-allelic homologous recombination between LILRB3 and LILRA6 as a mechanism for generating LILRA6 CNV and LILRB3 diversity. These data characterize LILRB3/LILRA6 genetic variation in more detail than previously described and underscore the need to determine their ligands.
Avoid common mistakes on your manuscript.
Leukocyte immunoglobulin–like receptors (LILRs; also known as ILTs and LIRs) comprise a family of inhibitory and activating receptors encoded by a gene cluster within the leukocyte receptor complex on human chromosome 19q13 (Anderson and Allen 2009; Wilson et al. 2000). Among 11 family members, inhibitory LILRB3 (ILT5, LIR3) and activating LILRA6 (ILT8) represent a unique homologous receptor pair characterized by highly polymorphic ectodomains (Bashirova et al. 2014; Borges et al. 1997; Colonna et al. 1997; Lopez-Alvarez et al. 2014; Torkar et al. 2000). LILRB3 was reported to be expressed primarily by myeloid cells based on flow cytometry (Colonna et al. 1999; Sloane et al. 2004; Tedla et al. 2003; Yeboah et al. 2020). Although cell surface antibody staining does not allow distinction between LILRB3 and LILRA6, it appears that LILRB3 expression dominates since antibody ligation results in inhibition of myeloid cells (Sloane et al. 2004; Yeboah et al. 2020) and mass spectrometry analysis of neutrophil lysates did not detect LILRA6, but did detect LILRB3 (Zhao et al. 2020).
Natural ligands for LILRB3 and LILRA6 are uncertain. Although recent work suggested that LILRB3 interacts with HLA class I (Ayukawa et al. 2021), this does not agree with structural predictions (Willcox et al. 2003) and other studies that failed to detect this interaction (Allen et al. 2001; Colonna et al. 1998; Jones et al. 2011). Other reported LILRB3 binding partners include angiopoietin-like proteins (Zheng et al. 2012), Staphylococcus aureus (Nakayama et al. 2007), and a cytokeratine-8-associated ligand on necrotic cells (Jones et al. 2016). Given recent work suggesting LILRB3 as a potential therapeutic target (Wu et al. 2021; Yeboah et al. 2020), it is important to further understand the biology of LILRB3 and LILRA6 receptors, including regulation of their function.
Genetic polymorphism may determine in part LILRB3 and LILRA6 ligand engagement. Genes encoding these receptors generate multiple protein variants differing in their ectodomains (Bashirova et al. 2014; Colonna et al. 1997; Hirayasu et al. 2021; Lopez-Alvarez et al. 2014). In addition, LILRA6 exhibits copy number variation (CNV), which appears to be the result of non-allelic homologous recombination (NAHR) (Bashirova et al. 2014; Lopez-Alvarez et al. 2014) and may regulate the balance between inhibitory and activating signaling. Due to the homology between LILRB3 and LILRA6, as well as LILRA6 CNV, genotyping SNPs in these genes is challenging. Published allelic variants were derived from studies of ≤ 20 individuals and publicly available genome-wide data are not reliable for SNP analysis in these genes. To estimate frequencies of alleles at the LILRB3 and LILRA6 loci, we sequenced the exons of LILRB3 and LILRA6 encoding signal peptides and ectodomains in 91 individuals of European descent with one or two copies of LILRA6 per diploid genome from a cohort of healthy blood donors described in our previous work (Bashirova et al. 2014).
LILRB3 and LILRA6 genomic fragments encompassing the first seven exons were amplified using gene-specific primers and each exon was sequenced by Sanger sequencing (Supplementary Table). Detailed information regarding LILRB3 and LILRA6 variation at the nucleotide and protein level is found in the Supplementary file. Among individuals with two LILRA6 copies (N = 86), a total of 53 distinct SNPs were detected in each gene that resulted in amino acid changes at 32 and 30 positions for LILRB3 and LILRA6, respectively. Nonsynonymous SNPs with frequencies > 5% in either LILRB3 or LILRA6 are listed in Fig. 1A (N = 39). The SNPs involved in amino acid changes at identical positions in the homologous regions of the two receptors showed substantially different frequencies in some cases (Supplementary Fig). These include several positions across the signal peptide and D1-D4 domains (shown in red in Fig. 1A, B). This distinct polymorphism in the signal peptide and ectodomain may potentially result in differential intracellular transport and/or ligand binding capacity of LILRB3 and LILRA6.
To estimate the frequency of protein variants (allotypes) in individuals with two copies of LILRA6, we inferred haplotypes composed of nonsynonymous SNPs using Haploview software (Barrett et al. 2005). Figure 2 shows six LILRB3 and four LILRA6 allotypes that were estimated at frequencies > 3% in our dataset. All of these were previously described in at least one study that determined alleles by cloning cDNA in small groups of individuals (Bashirova et al. 2014; Hirayasu et al. 2021; Lopez-Alvarez et al. 2014). Despite the homology between LILRB3 and LILRA6, none of the protein allotypes (i.e., signal peptide/ectodomain region) were identical between the two receptors. Phylogenetic analysis of amino acid sequences did not separate LILRB3 and LILRA6 variants into distinct clades, although the most common variants, LILRB3_1 and LILRA6_1, were the most divergent (Fig. 3). Overall, the phylogenetic tree is consistent with dynamic exchange of the genetic material between the two genes as a result of NAHR. The maximal divergence found in pairwise comparisons of protein sequences for alleles within each locus is 4.7% (LILRB3_1 and LILRB3_2) and 4.2% (LILRA6_1 and LILRA6_4). In contrast, divergence between the LILRB3 and LILRA6 allotypes can be considerably less, ranging from 1.6 to 5.4%. A homologous gorilla LILRB3 sequence (XP_030859787) averages 8.7% divergence from the human sequences (both LILRB3 and LILRA6). The human and gorilla lineages are thought to have separated some 8 million years ago. Thus, the substitution rate for these LILR genes approximates 1% divergence per million years. On this basis, the 4.7% divergence found among LILRB3 allotypes represents several million years divergence between allelic sequences.
Common LILRA6 allotypes were observed among the five individuals with a single LILRA6 copy, including two LILRA6_1, two LILRA6_3, and one LILRA6_2 allotypes. Interestingly, LILRB3 sequences in these same donors showed heterozygosity at positions -20 (A/T), -18 (A/T), -4 (H/R), or -94 (M/T) (Fig. 4A), which were either fixed or rarely polymorphic in LILRB3 (i.e., -20A, -18 T, -4R, and 94 M) among people with two copies of LILRA6 (Fig. 1A). Comparison of the LILRB3 sequences in these five individuals with the inferred LILRB3 and LILRA6 allotypes shown in Fig. 2 suggested the presence of one recombinant LILRB3 allotype in each person that is partially identical to LILRA6_1 or LILRA6_3 (see Fig. 4A, B as an example). The recombinant LILRB3 gene in each of these five subjects is very likely to have been generated by an ancestral NAHR event between a LILRA6 gene and a LILRB3 gene on homologous chromosomes, which eliminated the LILRA6 gene in the process (Bashirova et al. 2014; Lopez-Alvarez et al. 2014). Thus, we propose that in each of these five individuals, the recombinant LILRB3 gene (encoding the signal peptide and at least part of the ectodomain derived from LILRA6 and the remainder (including the signaling domain) derived from LILRB3) is present on the haplotype that is missing the LILRA6 gene. These data strongly support NAHR as a mechanism for LILRA6 CNV and LILRB3 diversification.
Our cohort is limited to individuals of European descent, and it is possible that these genes display population-specific diversity. Recent work indicated the frequent occurrence of a specific group of LILRB3 alleles, called lineage L3, among 15 Japanese individuals (Hirayasu et al. 2021), whereas this lineage was rarely seen in our cohort (Supplementary file; characteristic variant is 30Q). This population-specific distinction is consistent with the frequencies of rs76998994, a lineage L3-tagging SNP, in gnomAD genomes, which show an allelic frequency of 18% in East Asians vs. 1–2% in European individuals. Also, our dataset herein was somewhat biased by primarily including individuals with 2 copies of LILRA6. Previous work has shown that this configuration is present in only 2/3 of European individuals, whereas the other 1/3 have zero or more than 2 copies of LILRA6 per diploid genome (Bashirova et al. 2014). Given that NAHR, which likely caused the LILRA6 CNV, results in exchange of genetic fragments between LILRA6 and LILRB3, we expect that individuals with duplications and deletions of LILRA6 will carry more diverse sequences than that seen in the current study. Thus, more work needs to be done for accurate allelic characterization of this locus.
Our study is the first to estimate allelic frequencies of LILRB3 and LILRA6 genes in a sizable population group. Although our dataset may potentially miss some alleles if PCR/sequencing primers contain polymorphic sites affecting DNA amplification, such allelic dropouts would be rare given the consistency of our data with Hardy–Weinberg equilibrium (see Supplementary file) and previously published data (see Fig. 2). Extensive variation at the LILRB3/LILRA6 locus may translate to inter-individual variation in immune responses and risk of disease, emphasizing the need to determine ligands for LILRB3 and LILRA6 and the strength of their interactions as a function of genetic polymorphism.
References
Allen RL, Raine T, Haude A, Trowsdale J, Wilson MJ (2001) Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol 167:5543–5547
Anderson KJ, Allen RL (2009) Regulation of T-cell immunity by leucocyte immunoglobulin-like receptors: innate immune receptors for self on antigen-presenting cells. Immunology 127:8–17
Ayukawa S, Kamoshita N, Nakayama J, Teramoto R, Pishesha N, Ohba K, Sato N, Kozawa K, Abe H, Semba K, Goda N, Fujita Y, Maruyama T (2021) Epithelial cells remove precancerous cells by cell competition via MHC class I-LILRB3 interaction. Nat Immunol 22:1391–1402
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265
Bashirova AA, Apps R, Vince N, Mochalova Y, Yu XG, Carrington M (2014) Diversity of the human LILRB3/A6 locus encoding a myeloid inhibitory and activating receptor pair. Immunogenetics 66:1–8
Borges L, Hsu ML, Fanger N, Kubin M, Cosman D (1997) A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J Immunol 159:5192–5196
Colonna M, Nakajima H, Navarro F, Lopez-Botet M (1999) A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. J Leukoc Biol 66:375–381
Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, Lopez-Botet M (1997) A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 186:1809–1818
Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O’Callaghan CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A (1998) Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 160:3096–3100
Hirayasu K, Sun J, Hasegawa G, Hashikawa Y, Hosomichi K, Tajima A, Tokunaga K, Ohashi J, Hanayama R (2021) Characterization of LILRB3 and LILRA6 allelic variants in the Japanese population. J Hum Genet 66:739–748
Jones DC, Hewitt CR, Lopez-Alvarez MR, Jahnke M, Russell AI, Radjabova V, Trowsdale AR, Trowsdale J (2016) Allele-specific recognition by LILRB3 and LILRA6 of a cytokeratin 8-associated ligand on necrotic glandular epithelial cells. Oncotarget 7:15618–15631
Jones DC, Kosmoliaptsis V, Apps R, Lapaque N, Smith I, Kono A, Chang C, Boyle LH, Taylor CJ, Trowsdale J, Allen RL (2011) HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding. J Immunol 186:2990–2997
Lopez-Alvarez MR, Jones DC, Jiang W, Traherne JA, Trowsdale J (2014) Copy number and nucleotide variation of the LILR family of myelomonocytic cell activating and inhibitory receptors. Immunogenetics 66:73–83
Nakayama M, Underhill DM, Petersen TW, Li B, Kitamura T, Takai T, Aderem A (2007) Paired Ig-like receptors bind to bacteria and shape TLR-mediated cytokine production. J Immunol 178:4250–4259
Sloane DE, Tedla N, Awoniyi M, Macglashan DW Jr, Borges L, Austen KF, Arm JP (2004) Leukocyte immunoglobulin-like receptors: novel innate receptors for human basophil activation and inhibition. Blood 104:2832–2839
Tedla N, Bandeira-Melo C, Tassinari P, Sloane DE, Samplaski M, Cosman D, Borges L, Weller PF, Arm JP (2003) Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7. Proc Natl Acad Sci USA 100:1174–1179
Torkar M, Haude A, Milne S, Beck S, Trowsdale J, Wilson MJ (2000) Arrangement of the ILT gene cluster: a common null allele of the ILT6 gene results from a 6.7-kbp deletion. Eur J Immunol 30:3655–3662
Willcox BE, Thomas LM, Bjorkman PJ (2003) Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol 4:913–919
Wilson MJ, Torkar M, Haude A, Milne S, Jones T, Sheer D, Beck S, Trowsdale J (2000) Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci USA 97:4778–4783
Wu G, Xu Y, Schultz RD, Chen H, Xie J, Deng M, Liu X, Gui X, John S, Lu Z, Arase H, Zhang N, An Z, Zhang CC (2021) LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2-cFLIP-NF-kappaB signaling axis. Nat Cancer 2:1170–1184
Yeboah M, Papagregoriou C, Jones DC, Chan HTC, Hu G, McPartlan JS, Schiott T, Mattson U, Mockridge CI, Tornberg UC, Hambe B, Ljungars A, Mattsson M, Tews I, Glennie MJ, Thirdborough SM, Trowsdale J, Frendeus B, Chen J, Cragg MS, Roghanian A (2020) LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation. JCI Insight 5
Zhao Y, van Woudenbergh E, Zhu J, Heck AJR, van Kessel KPM, de Haas CJC, Aerts PC, van Strijp JAG, McCarthy AJ (2020) The orphan immune receptor LILRB3 modulates Fc receptor-mediated functions of neutrophils. J Immunol 204:954–966
Zheng J, Umikawa M, Cui C, Li J, Chen X, Zhang C, Huynh H, Kang X, Silvany R, Wan X, Ye J, Canto AP, Chen SH, Wang HY, Ward ES, Zhang CC (2012) Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature 485:656–660
Funding
This project has been funded in whole or in part with federal funds from the Frederick National Laboratory for Cancer Research, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This research was supported in part by the Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Bashirova, A.A., Kasprzak, W., O’hUigin, C. et al. Distinct frequency patterns of LILRB3 and LILRA6 allelic variants in Europeans. Immunogenetics 75, 263–267 (2023). https://doi.org/10.1007/s00251-022-01286-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00251-022-01286-1